LISATA THERAP.INC.DL-001 (8NE) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.223x

Based on the latest financial reports, LISATA THERAP.INC.DL-001 (8NE) has a cash flow conversion efficiency ratio of -0.223x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.25 Million ≈ $-3.80 Million USD) by net assets (€14.60 Million ≈ $17.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

LISATA THERAP.INC.DL-001 - Cash Flow Conversion Efficiency Trend (2021–2025)

This chart illustrates how LISATA THERAP.INC.DL-001's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 8NE liabilities breakdown for a breakdown of total debt and financial obligations.

LISATA THERAP.INC.DL-001 Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of LISATA THERAP.INC.DL-001 ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Maggie Beer Holdings Ltd AU:MBH	-0.265x
Coal Energy S.A. WAR:CLE	0.360x
Valbiotis SAS PA:ALVAL	-0.592x
Flagship Investments Ltd AU:FSI	-0.006x
SABUY TECHNOLOGY BK:SABUY-R	N/A
Canadian North Resources Inc. V:CNRI	0.006x
Elspec TA:ELSPC	0.028x
Pulsenmore Ltd. Ordinary Shares NASDAQ:PLSM	-0.344x

Annual Cash Flow Conversion Efficiency for LISATA THERAP.INC.DL-001 (2021–2025)

The table below shows the annual cash flow conversion efficiency of LISATA THERAP.INC.DL-001 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see 8NE market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€14.60 Million ≈ $17.07 Million	€-15.95 Million ≈ $-18.65 Million	-1.092x	-65.45%
2024-12-31	€29.32 Million ≈ $34.27 Million	€-19.36 Million ≈ $-22.63 Million	-0.660x	-57.85%
2023-12-31	€47.89 Million ≈ $55.99 Million	€-20.03 Million ≈ $-23.42 Million	-0.418x	-31.04%
2022-12-31	€66.32 Million ≈ $77.54 Million	€-21.17 Million ≈ $-24.75 Million	-0.319x	-32.01%
2021-12-31	€92.00 Million ≈ $107.56 Million	€-22.25 Million ≈ $-26.01 Million	-0.242x	--

About LISATA THERAP.INC.DL-001

F:8NE Germany Biotechnology

Market Cap

$28.11 Million

€24.04 Million EUR

Market Cap Rank

#24520 Global

#2121 in Germany

Share Price

€2.64

Change (1 day)

+0.76%

52-Week Range

€1.50 - €4.34

All Time High

€183.30